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examine how these definitions of 
addiction and their classifications 
of tobacco have been operational-
ized. Our focus is not on aca-
demic or clinical definitions of 
addiction, but rather on the appli-
cation of influential policy docu-
ments (the WHO and the surgeon 
generals’ reports) in arguments 
both in support of and in opposi-
tion to legal claims against the to-
bacco industry. These cases had a 
major role in public health 
through the regulation and indus-
try behavior they heralded.
We examined the testimony of 
8 scientists, evenly divided be-
tween witnesses for plaintiffs and 
defendants (the tobacco compa-
nies), for their views on addiction 
and how tobacco should be clas-
sified. Transcripts were identified 
from the Legacy Tobacco Docu-
ments Library’s Tobacco Deposi-
tions and Trial Testimony Ar-
chive, which reaches up to 2003. 
As far as possible, for each ex-
pert witness, we examined one 
transcript dating before and one 
after October 13, 1999, when 
Philip Morris, as part of a major 
public relations effort, publicly 
changed its stance from denying 
smoking was addictive to openly 
declaring it to be so. (Liggett 
changed its position on March 
WHEN 7 TOBACCO INDUSTRY 
chief executive officers (CEOs) 
swore before the US Congress in 
1994 that nicotine was not ad-
dictive, were they lying? What 
was meant by “addiction”? Ad-
diction is a concept widely used 
in medicine and by the lay pub-
lic. It holds important implica-
tions for systems of regulation, 
health care, modes of treatment, 
industry, litigation, and criminal 
justice. So how have definitions 
of addiction been reached?
Over the last 50 years, to-
bacco has been excluded from 
and then included in the cate-
gory of addictive substances. We 
examine contradictory definitions 
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of addiction used in litigation 
against tobacco companies dur-
ing the 1990s and 2000s. We 
trace the origins of these defini-
tions and some of the influences 
on their formation. (Throughout, 
we refer to “tobacco” rather than 
“nicotine” since understanding of 
the role of nicotine changed dur-
ing this period.)
These definitions were devel-
oped in the mid-20th century at 
official committees of the World 
Health Organization (WHO) and 
the US Surgeon General’s 
Advisory Committee (SGAC). We 
studied the committees’ reports, 
and in 2006, S. G. M. interviewed 
scientists serving on one of these 
committees and in the field, in-
cluding Charles LeMaistre, one of 
two surviving members of the 
SGAC; Donald Shopland, a 
library technician supporting the 
committee; and Jerome Jaffe, a 
psychiatrist researching addiction 
who later became the head of 
President Richard Nixon’s Special 
Action Office for Drug Abuse 
Prevention. Internal tobacco 
industry documents from the 
Legacy Tobacco Documents 
Library, University of California, 
San Francisco, were also analyzed.
Using testimony from lawsuits 
against tobacco companies, we 
Over the last 50 years, tobacco has been excluded from and then 
included in the category of addictive substances. We investigated 
influences on these opposing definitions and their application in 
expert witness testimony in litigation in the 1990s and 2000s. 
A scientist with ties to the tobacco industry influenced the selec-
tion of a definition of addiction that led to the classification of 
tobacco as a “habituation” in the 1964 Surgeon General’s Advi-
sory Committee report. Tobacco was later defined as addictive 
in the 1988 surgeon general’s report. 
Exper t witnesses for tobacco companies used the 1964 
report’s definition until Philip Morris Tobacco Company publicly 
changed its position in 1997 to agree that nicotine was addictive. 
Expert witnesses for plaintiffs suing the tobacco industry used 
the 1988 report’s definition, arguing that new definitions were 
superior because of scientific advance. Both sides viewed addic-
tion as an objective entity that could be defined more or 
less accurately. (Am J Public Health. 2008;98:1793–1802. 
doi:10.2105 AJPH.2007.114124) 
MEANINGS & MOTIVES
Experts Debating Tobacco Addiction
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illnesses and chronic pain. Opium 
relieved diarrhea, cough, pain, 
and insomnia in addition to its 
euphoric effects. Opium use was 
“normal.” It was given to children 
and adults, providing both men-
tal and physical relief, the medici-
nal effects shading imperceptibly 
into the social ones.7 Aspirin did 
not come onto the market until 
1899 or the sedative barbitu-
rates until 1906.8 In this context, 
addiction to opium was not a 
major concern.
EXCLUDING AND 
INCLUDING TOBACCO
Tobacco is a relative latecomer 
to the addiction model. In 
Britain, a major policy report 
from the Royal College of Physi-
cians referred to tobacco addic-
tion in 1962.9 The US surgeon 
general described smoking as a 
“habituation” rather than an 
addiction in 1964. The WHO’s 
International Classification of 
Diseases first included tobacco 
dependence as a diagnostic cate-
gory in 1977, and the American 
Psychiatric Association followed 
suit in 1980.10
However, the idea that regular 
tobacco smoking was difficult to 
give up was not new in the late 
20th century. Lay views of to-
bacco addiction were common, 
and fringe health practitioners 
early in the 20th century, such 
as John Harvey Kellogg, saw it as 
equivalent to other drugs: “The 
confirmed cigarette smoker is as 
thoroughly enslaved as is the 
opium smoker or the alcohol ine-
briate. He is a ‘dope’ fiend . . . an 
addict, and often requires the 
same restrictive measures to se-
cure reclamation as does the con-
firmed alcoholic or opium habi-
tué.”11 Meanwhile, US tobacco 
companies maintained a united 
position that tobacco was not ad-
dictive until 1997.
THE SURGEON GENERAL 
AND TOBACCO 
ADDICTION
In January 1964, the SGAC 
published its report Smoking and 
Health.12 Best known for its strong 
statements on cancer, the report 
also described tobacco as causing 
“habituation” rather than “addic-
tion.” It used verbatim definitions 
20, 1997.)1 This allowed us to 
consider whether the industry-
employed defense witnesses 
changed their views when their 
employers did. The selected tran-
scripts included substantial dis-
cussion of smoking addiction; if 
the discussion was brief, a third 
transcript was added.
DEFINING ADDICTION
What constitutes “addiction” 
and “dependence” has varied 
across time,2 between national 
contexts,3 and between sub-
stances.4 In the 18th century, the 
idea began to emerge that drunk-
enness was not a moral or reli-
gious weakness but a disease that 
required medical attention. In 
1804, the British doctor Thomas 
Trotter was the first to describe 
habitual drunkenness as a mental 
illness, and he likened the effects 
of spirits to the use of opium.5 
The term “addiction” was in 
widespread medical use by the 
early 20th century. As it became 
an accepted concept in medical 
and lay discourse, it began to re-
place such terms as “habit,” “in-
ebriety,” and “morphinomania,” 
and its definition also changed.6
Scientific and medical ideas 
about addiction have been heav-
ily influenced by their context, 
which includes perceptions of 
normalcy, associated harm, and 
how the substance is regulated. 
For instance, in 18th- and early 
19th-century England, opium 
was sold in ordinary grocers’ 
shops and used for a number of 
problems that were not neatly di-
vided into medical and nonmedi-
cal, as drug use is today. At this 
time, most of the population 
lacked formal health care, and 
self-medication was the norm. In-
fectious disease epidemics, vari-
able water quality, overcrowding, 
and poor housing led to frequent 
Tobacco executives swear that nico-
tine is not addictive, April 14, 1994, 
to the House of Representatives 
Committee on Energy and 
Commerce. 
Source. Stephen Crowley/The New York Times/
Redux.
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the text of Smoking and Health 
was finalized by mid-1963. The 
WHO Expert Committee did not 
meet until December of that 
year. According to LeMaistre, as 
they deliberated on the addiction 
issue, members of the SGAC 
were unaware that the WHO 
was about to change its defini-
tion. However, Maurice Seevers, 
who chaired the SGAC subcom-
mittee on tobacco and addiction, 
was also a member of the WHO 
Expert Committee. It is unknown 
whether Seevers was aware that 
the WHO was about to change 
its definitions.
USING THE WORLD 
HEALTH ORGANIZATION 
DEFINITIONS
In October 1962, Surgeon 
General Luther L. Terry an-
nounced the appointment of 10 
scientists to his Advisory Com-
mittee on Smoking and Health. 
Members were selected from 
names submitted by federal agen-
cies, voluntary health organiza-
tions, and the tobacco industry.18 
In a written communication with 
S.G.M. in 2006, Donald Shop-
land stated that a selection crite-
rion for prospective members 
was that they had never publicly 
taken a stand on tobacco and 
health or dependency.19 Their 
task was to review the scientific 
evidence from an objective stand-
point,20 but the result, according 
to Shopland, was that the com-
mittee relied more heavily on 
those with expertise in tobacco 
and addiction, such as Maurice 
Seevers.
In an interview with S.G.M., 
Jerome Jaffe said that Seevers 
was an esteemed professor of 
pharmacology at the University 
of Michigan. What is missing 
from other accounts is that he 
had received research funding 
world beyond science and medi-
cine. The WHO was concerned 
with the definitions’ use in shap-
ing international drug control 
policy. In the SGAC, one influen-
tial member may have been mo-
tivated to protect the interests of 
tobacco companies.
The WHO was established in 
1948 as a specialized agency of 
the United Nations, the latter 
having responsibility for interna-
tional drug control. The distinc-
tion between “habit” and “addic-
tion” was formed with an eye to 
policy questions: addictive drugs 
were subject to international con-
trols, whereas habit-forming sub-
stances only required national 
controls and warnings.16 This cre-
ated a number of inconsistencies. 
For instance, barbiturates were 
characterized as habit-forming at 
lower doses and addictive at 
higher doses, yet controls over 
their supply did not vary by 
dose. Sociologist Robin Room 
noted that by the WHO’s 1957 
definitions, alcohol was addictive, 
yet the United Nations had no in-
tention of bringing it under inter-
national controls.17 
The 1957 WHO definition re-
flected a scientific paradigm of 
addiction based on alcohol and 
opiates, which have dramatic 
withdrawal syndromes. Users 
also experienced chronic intoxi-
cation, and their drug use was 
problematic both for society and 
themselves. Addicts were consid-
ered mentally ill, requiring psy-
chiatric care. The WHO’s 1964 
change reflected a merging of the 
psychological and physical, de-
pathologizing the behavior and 
removing societal and contextual 
concerns from the definition. In-
toxication and tolerance were not 
considered necessary criteria for 
dependence.
In an interview with S.G.M., 
Charles LeMaistre revealed that 
from the WHO published in 
1957,13 in which “drug addiction” 
involved intoxication, an overpow-
ering desire to continue taking the 
drug and to obtain it by any 
means, a tendency to increase the 
dose to maintain the effect (toler-
ance), and a psychological and 
physical dependence on the drug, 
with adverse effects on both the 
individual and society. “Drug ha-
bituation” did not include intoxi-
cation, tolerance, or physical with-
drawal symptoms, and it focused 
on detrimental effects to the indi-
vidual. It characterized the urge 
to use a drug as “a desire” but 
“not a compulsion” for the “sense 
of improved well-being which it 
engenders.”12,13 The WHO re-
vised its definition in 1964, drop-
ping the habituation–addiction 
split and replacing it with the sin-
gle term “dependence.”
It was not until 1988 that the 
surgeon general publicly changed 
position by devoting an entire re-
port to “nicotine addiction,” bas-
ing its definition on criteria from 
the American Psychiatric Associ-
ation, the National Institute for 
Drug Abuse, and the 1964 
WHO revision. The 1988 sur-
geon general’s report used the 
terms “addiction” and “depen-
dence” synonymously.14 Its three 
main conclusions were that to-
bacco was addicting, nicotine was 
the drug in tobacco that caused 
addiction, and the pharmacologi-
cal and behavioral processes that 
determined tobacco addiction 
were similar to those for heroin 
and cocaine.15
HOW THE DEFINITIONS 
WERE REACHED
The WHO’s 1957 definitions, 
and possibly their inclusion in 
Smoking and Health, were influ-
enced by concerns about how 
they would be used in the wider 
John Harvey Kellogg (1852–1943), 
who compared tobacco smoking 
with opium addiction. 
Source. Courtesy of the Community Archives of 
Heritage Battle Creek, Battle Creek, Michigan.
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work in Seevers’s view of addic-
tion: in a 1962 paper, he had crit-
icized the WHO’s 1957 defini-
tions, stating that “habituation” 
and “addiction” “are beyond 
salvage for the scientific descrip-
tion of drug effects and should 
be abandoned.”27 Given his 
public misgivings about the 
1957 definitions, it is surprising 
that Seevers was insistent on 
their use.
Kluger concluded that when 
the SGAC decided that smoking 
was only a habit, “the tobacco 
industry was rewarded for its 
championing of Seevers as a 
member of the Surgeon General’s 
elite panel.”28 However, although 
Seevers was approved by the 
industry, the American Cancer 
Society had actually nominated 
him. In an internal Philip Morris 
document reviewing scientists 
suggested for the SGAC, Seevers 
is described as “an excellent 
choice; outstanding reputation 
and very down-to-earth; unless 
evidence is clear cut he would 
not go along.”29 Whether or 
not this endorsement influenced 
the selection process is unknown.
As historians have observed, 
the history of a substance partly 
depends on the perceived status 
of its users.30 In the mid-20th 
century, smoking was normal in 
society. Several SGAC members 
smoked, whereas addiction had 
greater stigma than it has today. 
Addicts were viewed as incurable 
and psychologically abnormal, 
which was hard to align with the 
large smoking population.31 Un-
like habituation, commented the 
SGAC, 
It is generally accepted among 
psychiatrists that addiction to 
potent drugs is based upon seri-
ous personality defects from un-
derlying psychological or psychi-
atric disorders which may 
become manifest in other ways 
if the drugs are removed.32 
of some to stop using it, but that 
they agreed with Seevers that 
they could not depart from the 
authority of the WHO’s classifi-
cation. This suggests that at least 
two competing ideas of addiction 
were current at that time.
Seevers’s reported insistence 
on the WHO definitions may 
have reflected the interests of the 
tobacco industry. In 1960, as a 
member of the American Medi-
cal Association’s (AMA’s) Council 
on Drugs, Seevers intervened to 
stop it from issuing a statement 
against smoking. An internal note 
from R.K. Heimann, assistant to 
the president, written to the pres-
ident and vice president of Amer-
ican Tobacco, described Seevers 
as “a friend of the Company’s Re-
search Department”; Heimann 
reported that he and another 
council member with links to the 
industry had expressed doubt 
over the evidence for risks from 
cigarettes. As a result, the Coun-
cil on Drugs concluded that there 
was insufficient evidence to issue 
a statement in support of the 
“anticigarette theory.”24 Seevers 
also fed information to American 
Tobacco on the actions of AMA 
regarding smoking and health 
policy discussions in the early 
1960s, and he sought the 
company’s advice on nomina-
tions to AMA committees.25
Seevers could have viewed the 
scientific evidence linking smok-
ing and lung cancer as insufficient 
before his involvement with the 
American Tobacco Company, 
which then chose him as a consul-
tant because of his existing views. 
Epidemiological proof of causa-
tion in chronic disease was an 
emerging methodology, and skep-
ticism could be seen as a legiti-
mate response to this evidence 
prior to 1964.26 However, there 
is suggestive but not conclusive 
evidence of tobacco interests at 
and held a consultancy from the 
American Tobacco Company 
when invited to join the SGAC.21 
He declared the consultancy to 
the Office of the Surgeon Gen-
eral, resigning for the duration of 
his committee membership. An 
internal American Tobacco Com-
pany memorandum from E. S. 
Harlow, assistant managing direc-
tor for research, to H.R. Hamner, 
vice president, and W.R. Harlan, 
managing director of research 
and development, explained:
Dr Seevers has written to the 
Surgeon General accepting a 
firm appointment to the subject 
panel. The Surgeon General’s 
office did not feel that Dr 
Seevers’ consulting arrangement 
with The American Tobacco 
Company had any bearing on 
his appointment. However, as 
he had previously indicated to 
them it was his intention to re-
sign his consultantship, he is 
doing so by letter to HRH 
[Hamner]. After his work on the 
panel is completed he definitely 
would like to be re-employed by 
us as a consultant.22
This intention to resume the 
links suggests that the resignation 
was largely cosmetic. According 
to LeMaistre, Seevers convinced 
the committee that it must use 
the WHO definitions of “habitua-
tion” and “addiction,” which clas-
sified nicotine as a habit rather 
than an addiction. Richard 
Kluger also noted that Seevers 
was able to persuade the rest of 
the committee to adopt this defi-
nition of addiction because of his 
dominating personality and the 
committee’s lack of alternative 
expertise on the subject to chal-
lenge his position.23
In his interview, LeMaistre re-
called that the rest of the commit-
tee members considered smok ing 
to be addictive, by which they 
meant “an overpowering need to 
place the use of the drug above 
all other factors” and an inability 
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Conversely, it was perhaps 
easier to categorize smokers as 
addicts in 1988 because the 
smoking population had become 
increasingly associated with 
lower educational attainment and 
socioeconomic status. Historian 
Allan Brandt suggests that 
in a culture prone to stigmatize 
its poor and disfavored, chang-
ing perceptions about the ‘aver-
age smoker’ eased the growing 
attribution of addiction.33 
ADDICTION IN TOBACCO 
LITIGATION, 1990 TO 2003
Civil cases against US tobacco 
companies have been brought by 
those with diseases linked to 
smoking, or by their relatives, 
since at least the 1960s34; these 
cases have partly turned on the 
question of addiction. Paul 
Knopick, a senior employee at 
the Tobacco Institute, reported in 
a 1980 internal memorandum 
that Philip Morris’s legal advisors 
had cautioned
that the entire matter of addic-
tion is the most potent weapon 
a prosecuting attorney can have 
in a lung cancer/cigarette case. 
We can’t defend continued 
smoking as a ‘‘free choice’’ if 
the person was ‘‘addicted.’’35 
In litigation, expert witnesses 
explained the scientific evidence 
on tobacco and its addiction po-
tential in order to strengthen or 
diminish the plaintiff’s responsi-
bility for smoking.
All defense expert witnesses 
whose transcripts we examined 
were scientists employed by 
tobacco companies. Witnesses 
for the plaintiffs worked in a 
variety of settings, including uni-
versities and government and as 
private consultants (Table 1). As 
connections to the tobacco indus-
try and conflicts of interest have 
TABLE 1—Defense and Plaintiff Witnesses Quoted in This Article, With Their Qualifications and Affiliations
 Name Qualifications and Affiliations
Defense witnesses
 John Robinson, PhD  Psychologist. Worked at Bowman Gray School of Medicine, Wake Forest University in Winston-
Salem, NC, then took a scientific post at RJ Reynolds in 1981. Employed as a senior 
behavioral scientist and director of smoking behavior and Physiology Division during which 
time he studied smoking behavior.36
 Donald DeBethizy, PhD  Toxicologist. Worked for RJ Reynolds from 1985 to 2000, reaching the position of vice 
president of product evaluation. Also served for 10 years as a science media liaison for the 
company from 1990. After leaving RJ Reynolds, he went into business developing nicotine 
analogues in conjunction with RJ Reynolds. Developed and led a Positive Aspects of Nicotine 
Team project, in which John Robinson was also involved, to defend the industry by creating a 
debate around smokers’ motivations and to fight efforts to classify nicotine as addictive.37
 Richard Carchman, PhD  Toxicologist, Medical College of Virginia. In 1988 went to Philip Morris, where he rose to the 
position of vice president of research, development, and engineering until his retirement in 
February 1999. He then continued as a consultant to the company.38
 Sharon Boyse (later Blackie), PhD  Psychologist, also trained in pharmacology. Worked for British American Tobacco (BAT) as a 
senior scientific adviser in London from 1986 to 1991 and from 1994 to 1996 as a 
consultant to the firm. Late that year, joined Brown and Williamson, a subsidiary of BAT, first 
as director of scientific affairs and then as director of applied research.39
Plaintiff witnesses 
 Neal Benowitz, MD  Professor of medicine at the University of California, San Francisco, since 1974—worked at 
San Francisco General Hospital and had a special interest in pharmacology and toxicology. 
One of the four editors of the 1988 surgeon general’s report.
 John Hughes, MD  Board-certified psychiatrist, since 1985 a professor in the Departments of Psychiatry, 
Psychology, and Family Practice at the University of Vermont. Studied a number of topics 
related to tobacco and nicotine addiction, including nicotine replacement therapy and the 
role of motivational advice. A director of University of Vermont’s College of Medicine Human 
Behavioral Pharmacology Laboratory. 
 Jack Henningfield, PhD  Professor of psychology and psychopharmacology. Carried out extensive work on tobacco and 
nicotine while at the National Institute for Drug Abuse and was also a professor in the 
Department of Psychiatry and Behavioral Sciences at Johns Hopkins University School of 
Medicine. Also held a senior post in the consulting firm Pinney Associates, through which his 
expert witness work was arranged. One of the four editors of the 1988 surgeon general’s 
report.
 Richard Hurt, MD  Professor of medicine at the Mayo Clinic, with expertise in the pharmacology of nicotine 
and the treatment of nicotine use. Joined the Mayo Clinic in 1973 and took charge of its 
Nicotine Dependence Center in 1988. The center treated patients trying to stop smoking 
and carried out research and education. Also conducted research on the activities of the 
tobacco industry.40
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that the practice of smoking 
should be labeled a habit or an 
habituation”; his January 1999 
deposition maintained this posi-
tion.49 Unfortunately, no post–
October 1999 transcript was 
available for Robinson. In 1997, 
DeBethizy denied that nicotine 
was addictive, whereas in 2000 
he testified, “[W]ith the definition 
that’s commonly used today, I 
would believe that nicotine is ad-
dictive,” that it was a reason peo-
ple smoked, and that it played a 
part in smoking behavior.50
Before Philip Morris changed 
its public stance on addiction, 
toxicologist Richard Carchman 
told the court: 
All I know is that some people 
who smoke cigarettes have a 
hard time quitting. Whether it’s 
related to the nicotine or some 
other feature of the cigarette, I 
don’t know.51 
His position changed slightly by 
2000: 
I make a distinction between 
smoking and nicotine . . . nico-
tine has to be viewed within the 
context of smoking, not nicotine 
itself. And smoking is a complex 
behavior that has attributes to it 
that can make it difficult for 
people to stop smoking. Is nico-
tine a part of it? . . . Yes, it can 
be.52
Sharon Boyse (later Blackie), a 
British psychologist trained in 
pharmacology working for Brit-
ish American Tobacco,53 fol-
lowed the 1964 SGAC report’s 
definition. She likened smoking 
to indulgent eating:
I think there are many things 
that you enjoy that can be im-
mensely difficult to quit. I do 
not believe, however, that diffi-
culty in quitting is an indication 
of whether or not something is 
addictive. I think people who go 
on diets have the greatest diffi-
culty in the world giving up 
cakes and chocolate. But I 
wouldn’t, in my wildest dreams, 
his study of scientists giving ad-
vice in policy committees, has 
described this process as “science 
on stage,” where credibility is 
produced through a range of the-
atrical techniques regulating the 
presentation of information and 
the relationship between scien-
tists and their audience.46 Similar 
methods may be seen in the pre-
sentation of expert witnesses in 
litigation.
DEFENSE EXPERT 
WITNESSES
All four expert witnesses for 
the tobacco industry whose testi-
mony we examined argued 
against definitions that character-
ized tobacco or nicotine as addic-
tive. Two explicitly used the defi-
nition of the 1964 SGAC report, 
although this had been aban-
doned by the WHO and super-
seded by the 1988 surgeon gen-
eral’s report. All questioned the 
role of nicotine in people’s diffi-
culty in quitting, although some 
changed their views in line with 
Philip Morris’s position in Octo-
ber 1999. None argued against 
the concept of addiction per se, a 
strategy used by the industry in 
other arenas.47 
For example, RJ Reynolds ex-
pert witness Donald DeBethizy, a 
toxicologist, considered in 1997 
that the change in definition 
from the 1964 SGAC report to 
that of 1988 was because “There 
was a shift in thinking about 
what constituted addiction, and 
the definition was broadened to 
be able to include nicotine and 
smoking,” which he considered 
to be a mistake that blurred the 
distinctions between different 
types of activities.48 Similarly, 
psychologist John Robinson de-
clared in 1991, “I would agree 
with the ’64 Surgeon General’s 
Report which said . . . essentially 
historically been concealed,41 we 
selected only defense experts 
employed by the industry to be 
certain of their financial links.
An important point of dispute 
between plaintiff and defense ex-
pert witnesses was their defini-
tion of addiction. By the 1990s, 
many scientific studies suggested 
that nicotine was addictive by the 
definitions given in the 1988 sur-
geon general’s report.42 Before 
October 1999, however, expert 
witnesses for the defense fre-
quently invoked the earlier defi-
nitions of “habituation” and “ad-
diction” given in Smoking and 
Health  in 1964. They claimed 
that tobacco was merely a habit 
that could be broken, equivalent 
to any other pleasurable activity. 
After October 1999, when most 
companies had declared tobacco 
to be addictive, defense experts 
changed their views in line with 
their employers.
THE ROLE OF EXPERTISE 
IN LITIGATION
In an age when the very no-
tion of expertise is contested, its 
role in litigation remains contro-
versial, even among expert wit-
nesses themselves.43 Historian 
David Rothman views the work 
of expert witnesses as advocacy 
rather than scholarship but con-
siders both activities equally le-
gitimate. From his own experi-
ences, he concluded that the 
difference was not in objectivity 
but rather the focus of the pro-
cess; in litigation “the scope of 
analysis is narrowed, the imagi-
nation is constrained, and the cu-
riosity, curtailed.”44 Allan Brandt 
was wary of his scholarship being 
“dismissed as ‘advocacy,’ ” but he 
testified to provide what he con-
sidered a fuller analysis than that 
presented by tobacco industry 
experts.45 Stephen Hilgartner, in 
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suggest that they are addicted 
to cakes and chocolate.54
After 1999, she appeared 
more positive toward the 1988 
surgeon general’s definition, but 
rejected comparisons with heroin 
addiction.55 In 2003, she consid-
ered smoking “a very complex 
behavior” and that people did 
not smoke purely for the nico-
tine.56 Both Carchman and Boyse 
described tobacco as hard to give 
up but did not believe this consti-
tuted addiction, echoing the 
SGAC’s 1964 observation: 
[C]orrectly designating the 
chronic use of tobacco as habit-
uation rather than addiction 
carries with it no implication 
that the habit may be broken 
easily.57 
PLAINTIFF EXPERT 
WITNESSES
Using the definition of the 
1988 surgeon general’s report, 
the four experts for the plaintiffs 
whose testimony we examined 
claimed that tobacco produced 
dependence or addiction. How 
did these scientists account for 
the change in definition from 
1964 and their preference for 
the new definition? Neal Benow-
itz, one of the four editors of the 
1988 surgeon general’s report, 
characterized the change as the 
result of scientific advance. The 
1964 SGAC report labeled nico-
tine habituating because, accord-
ing to Benowitz, scientists “didn’t 
fully understand the pharmacol-
ogy of nicotine.”58 He said in 
2001 that 
I can’t think of [any scientist] in 
recent times who has used ‘ha-
bituation.’ That was a term that 
was developed . . . by the 
World Health Organization in 
1957 and really sets up a dis-
tinction between that and ad-
diction. That doesn’t make 
physiological sense. So it is not 
used any more.”59
John Hughes also explained in 
1990 that there were many 
statements about dependence in 
previous surgeon general’s re-
ports that were no longer true: 
“[O]ur science is going to dis-
prove a lot of things that we said 
earlier. It’s part of the nature of 
doing science.”60 In 1994, 
Hughes repeated his view that 
the change resulted from scien-
tific progress.61
Both Hughes and Benowitz 
agreed that altered perceptions 
of addiction also accounted for 
the definition’s change. In 1997, 
Benowitz remarked that in 1964, 
people thought of addicts as 
being totally crazed and out of 
their mind and violent and 
criminal. There was a very ste-
reotypical description of addic-
tion then which is different than 
now.62 
Hughes added that in the 1920s 
and 1930s, 
most people, and unfortunately 
the medical profession of which 
I’m a part of, thought that alco-
holism was a willful disorder 
that there was no such thing as 
alcohol dependence, these were 
just weak-willed people . . . the 
same sorts of things have hap-
pened with other drugs that 
we’ve recognized as being drugs 
of dependence over time.63 
Hughes and Benowitz pre-
sented these changes in attitude 
as the result of greater enlighten-
ment, with substance use and ad-
diction having an objective real-
ity that had to be described as 
accurately as possible.
Jack Henningfield and Richard 
Hurt also appearing for the plain-
tiffs, claimed that if the tobacco 
industry had not kept back its 
own research from the surgeon 
general during the 1964 report’s 
preparation, it would have defined 
nicotine as addictive. Hurt conjec-
tured in 1997 that with access to 
the internal documents of the to-
bacco industry, which referred to 
nicotine as an addicting sub-
stance, the SGAC’s conclusions 
might have been different.64 He 
argued that the industry’s own in-
ternal documents would have 
shown that nicotine caused physi-
cal dependence, tolerance, and 
withdrawal symptoms, thus ex-
cluding it from the “habituation” 
category.65 However, the lack of 
intoxication and the absence of 
perceived pathology among to-
bacco users would still have been 
obstacles to use of the WHO clas-
sification of addiction.66
Henningfield served with Be-
nowitz as a scientific editor on 
the 1988 surgeon general’s re-
port. He recognized that had the 
concealed industry research been 
available to the 1964 SGAC, 
there would still have been ob-
stacles to defining nicotine as ad-
dictive but that 
nicotine, as was described in 
the report, was clearly in a gray 
area, where judgment calls were 
made. It was recognized to be 
an important pharmacological 
factor in smoking, that met the 
criteria for what was then called 
habituating. It was not put into 
the addicting category.67
When asked whether nicotine 
could even today be classified as 
addictive by the 1964 SGAC 
definitions given the chronic in-
toxication criterion, Henningfield 
replied, “It depends how heavily 
they weighted that factor.”67 The 
four experts for the plaintiffs re-
mained constant in their views 
before and after October 1999.
SCIENTIFIC 
DEVELOPMENTS
Nicotine has been the subject 
of increasingly intensive scientific 
research since 1964. Could 
changes in scientific knowledge 
explain the surgeon general’s 
moving nicotine from a “habit” to 
an “addiction” in 1988 or the in-
dustry’s switch in 1999?
In 1980, the first work show-
ing specific nicotine binding sites 
in the brain appeared,68 with sub-
sequent findings on the role of 
nicotine in neurotransmitter sys-
tems. This showed that tobacco 
could act in ways similar to those 
of addictive drugs. By 1988, the 
evidence showed a neurobiologi-
cal basis for addiction, which was 
referenced in the surgeon gener-
al’s report of that year.69
However, the neuroscience was 
only one factor of several. In 
1980, before these scientific de-
velopments, the American Psychi-
atric Association revised its Diag-
nostic and Statistical Manual of 
Mental Disorders, introducing di-
agnoses of “tobacco dependence” 
and “tobacco withdrawal.”70 
These conditions, which were be-
haviorally based, influenced the 
definition used in the 1988 sur-
geon general’s report.71 
Aside from evidence from the 
1980s of a neurobiological basis 
for addiction, there do not seem 
to be major scientific develop-
ments that would explain the in-
dustry’s position change in 
1999. In the 1990s, imaging 
studies were conducted showing 
that nicotine affects the brain,72 
but these do not prove addiction. 
Richard Carchman, former Philip 
Morris vice president of re-
search, explained his employer’s 
position change when he ap-
peared as an expert witness in 
the company’s defense. Asked 
whether anything had changed 
from a scientific perspective 
between 1994 and 2000 with 
respect to the addictiveness of 
cigarette smoking, he replied, 
“Nothing.”73
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CONCLUSIONS
To sum up, “addiction” or “de-
pendence” are malleable con-
cepts situated in specific social, 
political, and scientific contexts, 
but the parties involved in litiga-
tion spoke more as if they were 
universal scientific truths to be 
unveiled or denied. At the same 
time, expert witnesses for each 
side used different definitions. 
Experts appearing for the defen-
dants favored the 1964 SGAC 
report’s conclusion that tobacco 
smoking was a habituation rather 
than an addiction, a definition 
taken from the WHO’s 1957 re-
port, which in turn was influ-
enced by concerns about interna-
tional drug control policy, not 
just “scientific” inquiry. Despite 
the alternative understandings of 
addiction in scientific currency at 
the time, the use of the WHO 
definitions was largely encour-
aged by Maurice Seevers, who 
had links with the tobacco indus-
try. Whether or not the 1964 
SGAC report’s conclusion that to-
bacco was habit-forming rather 
than addictive was the result of 
the tobacco industry’s influence 
is difficult to determine. The 
plaintiffs’ experts used the 1988 
surgeon general’s report defini-
tion, which was based on criteria 
from the American Psychiatric 
Association, the National Institute 
for Drug Abuse, and the revised 
1964 WHO definition. Clearly, 
to the scientist, whether or not 
tobacco is addictive depends on 
the definition used and how it is 
applied. Although using different 
definitions, all the expert wit-
nesses argued from a positivist 
framework and used the same 
source as an authority: the US 
surgeon general.
And what of the seven CEOs 
testifying before Congress? It 
seems that at least one of them 
may have been using the older 
WHO definition of addiction. 
James Johnston, chairman and 
CEO of RJ Reynolds Tobacco 
Company, declared that “ciga-
rettes and nicotine clearly do not 
meet the classic definition of ad-
diction. There is no intoxica-
tion.”74
Were these standpoints 
equally valid? Addiction is a flex-
ible concept that depends on so-
cial priorities as well as scientific 
findings. Scientific inquiry in turn 
is shaped by these social priori-
ties. Our study suggests that such 
flexibility and changes over time 
can be manipulated or exploited 
for political and economic inter-
ests. It seems likely that the de-
fense witnesses’ preference for 
the older definition was influ-
enced by a desire to protect their 
employers. 
In the world of illicit drugs, 
where commodities are produced 
and distributed through criminal 
sources, civil litigation against 
drug suppliers is absent. Re-
searchers do not receive funding 
from these sources, and the idea 
of separating “habit” and “addic-
tion” has been discarded. This in 
part has resulted from moves 
away from an addiction para-
digm based around alcohol and 
opiates and physical withdrawal 
syndromes to one that empha-
sizes craving. Laboratory science 
has shown that psychological and 
physical addiction cannot be sep-
arated, because they influence 
each other.75 
The tobacco companies’ ex-
pert witnesses changed their po-
sitions on the validity of the 
1988 surgeon general’s report 
definition and the importance of 
nicotine only after their employ-
ers had reversed their public po-
sition on the addictiveness of to-
bacco and nicotine. This 
happened at a time when there 
were no major changes in the sci-
entific knowledge of addiction. 
Such a process could be termed 
“corporate science,” where con-
clusions are based on “top down” 
organizational policy decisions 
rather than drawn from scientists’ 
empirical research. 
It is harder to say whether the 
plaintiff witnesses’ definition was 
influenced by their worldly con-
cerns, such as an opposition to 
the role of the tobacco industry 
in the spread of tobacco-related 
disease, or involvement in the 
medical treatment of tobacco 
use. The plaintiffs used the most 
up-to-date definition at the time 
of trial, which would be consis-
tent with their stated beliefs that 
scientific progress led to changes 
in the definition over time. Cer-
tainly their view that tobacco 
was addictive preceded their in-
volvement in litigation: two of 
them had used this definition 
since at least 1988, when they 
had introduced it into the sur-
geon general’s report. The extent 
to which a researcher’s scholar-
ship may be influenced by his or 
her service as an expert witness 
is a question that remains to be 
explored.
Plaintiff experts’ views could 
be characterized as arising from 
scientific, industrial, and social 
changes that resulted in the per-
ception of tobacco use as an ad-
diction. But was this adoption 
purely the result of scientific 
progress, as plaintiff witnesses 
contend? Since the 1964 SGAC 
report was published, tobacco 
smoking has become more stig-
matized and addiction has be-
come less so in many Western 
countries. The medical profession 
and the pharmaceutical industry 
have developed clinical treat-
ments of tobacco addiction, med-
icalizing a behavior that was con-
sidered normal in the 1950s and 
1960s for all levels of society. It 
has therefore become easier to 
perceive smoking as a medical 
condition similar to illicit drug 
use. We do not suggest that the 
plaintiff expert witnesses were di-
rectly influenced by economic in-
terests as the defense witnesses 
were, but science cannot be de-
tached from the social structures 
and beliefs of which scientists are 
a part. Although it may not be 
possible to detach science from 
social structures, efforts can be 
made to separate scientific pro-
cesses from unabashed self-inter-
est. We should continue to exam-
ine carefully the meaning behind 
commonly used terms, the inter-
ests of those defining them, and 
the social contexts in which defi-
nitions are created. ■
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